MLKL Protein, Human (His)
Based on 3 publication(s) in Google Scholar
MLKL protein is a pseudokinase that plays a key role in TNF-induced necroptosis. Despite lacking intrinsic kinase activity, it is activated through RIPK3 phosphorylation, leading to homotrimerization, plasma membrane localization, and execution of necroptosis. MLKL Protein, Human (His) is the recombinant human-derived MLKL protein, expressed by E. coli , with N-6*His labeled tag.
- Species: Human
- Source: E. coli
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Technical Parameters
-
Product Properties
- Documentation
- Help & FAQs
Biological Activity
MLKL protein is a pseudokinase that plays a key role in TNF-induced necroptosis. Despite lacking intrinsic kinase activity, it is activated through RIPK3 phosphorylation, leading to homotrimerization, plasma membrane localization, and execution of necroptosis. MLKL Protein, Human (His) is the recombinant human-derived MLKL protein, expressed by E. coli , with N-6*His labeled tag.
MLKL, a pseudokinase, plays a pivotal role in TNF-induced necroptosis, a programmed cell death process characterized by plasma membrane damage and calcium influx. Despite lacking intrinsic protein kinase activity, MLKL is activated upon phosphorylation by RIPK3. This activation leads to homotrimerization, plasma membrane localization, and execution of necroptosis. Additionally, in response to orthomyxoviruses infection, MLKL can undergo nuclear necroptosis triggered by ZBP1 activation, resulting in disruption of the nuclear envelope and release of cellular DNA into the cytosol. MLKL's necroptotic function is facilitated by its binding to highly phosphorylated inositol phosphates, such as inositolhexakisphosphate (InsP6). This binding not only mediates the release of an N-terminal auto-inhibitory region but also requires RIPK3-dependent phosphorylation for full activation. Necrosulfonamide, a specific inhibitor of necroptosis, targets Cys-86 and effectively inhibits MLKL function.
The kinase activity of this recombinant protein is testing in progress, we cannot offer a guarantee yet.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy. [Abstract]2025 May 3;16(1):4128. PMID: 40319089 -
J Med Chem
Discovery of Novel MLKL PROTAC Degraders for the Treatment of Hepatocellular Carcinoma via Promoting Parthanatos. [Abstract]2026 Mar 26;69(6):7032-7047. PMID: 41834604 -
J Med Chem
Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis. [Abstract]2024 Sep 12;67(17):15353-15372. PMID: 39180479
Technical Parameters
-
Species Human
-
Source E. coli
-
Tag N-6*His
-
Accession
Q8NB16 (M1-K471)
-
Gene ID197259
-
Molecular Construction
-
N-term
-
6*His
-
MLKL (M1-K471)
Accession # Q8NB16 -
C-term
-
-
Protein Length
Full Length
-
Synonyms
MLKL; FLJ34389; Mixed Lineage Kinase Domain Like Pseudokinase; HMLKL; Mixed Lineage Kinase Domain-Like Protein; Mixed Lineage Kinase Domain-Like
-
AA Sequence
MENLKHIITLGQVIHKRCEEMKYCKKQCRRLGHRVLGLIKPLEMLQDQGKRSVPSEKLTTAMNRFKAALEEANGEIEKFSNRSNICRFLTASQDKILFKDVNRKLSDVWKELSLLLQVEQRMPVSPISQGASWAQEDQQDADEDRRAFQMLRRDNEKIEASLRRLEINMKEIKETLRQYLPPKCMQEIPQEQIKEIKKEQLSGSPWILLRENEVSTLYKGEYHRAPVAIKVFKKLQAGSIAIVRQTFNKEIKTMKKFESPNILRIFGICIDETVTPPQFSIVMEYCELGTLRELLDREKDLTLGKRMVLVLGAARGLYRLHHSEAPELHGKIRSSNFLVTQGYQVKLAGFELRKTQTSMSLGTTREKTDRVKSTAYLSPQELEDVFYQYDVKSEIYSFGIVLWEIATGDIPFQGCNSEKIRKLVAVKRQQEPLGEDCPSELREIIDECRAHDPSVRPSVDEILKKLSTFSK
-
Predicted Molecular Mass
58.5 kDa
-
Molecular Weight
Approximately 59-64 kDa, based on SDS-PAGE under reducing conditions.
-
Purity
≥ 90%, as determined by reducing SDS-PAGE.
Product Properties
Lyophilized powder
1.Lyophilized from a 0.22 μm filtered solution of 10 mM Tris-HCl, 1 mM EDTA, 6% trehalose, pH 8.0.
2.Lyophilized from a 0.22 μm filtered solution of 20 mM HEPES, 6% trehalose, pH 7.4.
3.Lyophilized from a 0.22 μm filtered solution of PBS, 6% trehalose, pH 7.4.
Please refer to the lot-specific COA for specific buffer information.
Note: For SPR assay, please replace the buffer. Primary amine components (e.g., Tris, imidazole) can affect protein-coupled chips.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O.
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
-
Data Sheet (238 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz
